DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2263449/gilead-gild-q1-loss-narrower-than-expected-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2263449 Apr 26, 2024 - Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales. 0

https://www.fool.com/earnings/call-transcripts/2024/04/25/gilead-sciences-gild-q1-2024-earnings-call-transcr/?source=iedfolrf0000001 Apr 25, 2024 - GILD earnings call for the period ending March 31, 2024. 0

https://www.zacks.com/stock/news/2262804/gilead-gild-reports-q1-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2262804 Apr 25, 2024 - Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2262696/gilead-sciences-gild-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2262696 Apr 25, 2024 - Gilead (GILD) delivered earnings and revenue surprises of 11.41% and 5.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.fool.com/investing/2024/04/05/got-5000-these-3-high-yielding-dividend-stocks-are/?source=iedfolrf0000001 Apr 05, 2024 - All of these stocks pay generous dividends that income investors will appreciate. 0

https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001 Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 0

https://www.zacks.com/commentary/2228528/top-research-reports-for-merck-servicenow-blackstone?cid=CS-ZC-FT-research_daily-2228528 Feb 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX). 0

https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390 Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings. 0

https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414 Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline. 0

https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector. 0